PhaseRx, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PZRXQ research report →
About the company
PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells.
- CEO
- Robert W. Overell
- IPO
- 2016
- Employees
- 10
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $1.17K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 101.72%
- ROIC
- -122.20%
- Revenue
- $0 · -100.00%
- Net Income
- $-20,137,000 · -172.97%
- EPS
- $-2.68 · -185.11%
- Op Income
- $-18,330,000
- FCF YoY
- -63.80%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.55
- Avg Volume
- 275.68
Get TickerSpark's AI analysis on PZRXQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PZRXQ coverage
Recent articles, reports, and earnings notes.
No research on PZRXQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PZRXQ report →Similar companies
Peers in the same neighborhood.